{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.5","upperLimit":"16.3","value":"12.2"},{"comment":"The 95% confidence interval upper limit was not estimable (i.e. insufficient number of participants with events).","groupId":"OG001","lowerLimit":"10.3","upperLimit":"NA","value":"13.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"Overall survival (OS) (Phase II Analysis Group 2 - Initial Treatment Period). Kaplan-Meier methodology will be used to estimate the distribution of OS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.","id":"OG000","title":"Phase II - Analysis Group 2 MLN0128"},{"description":"Patients receive 400mg Pazopanib orally once daily over a 4-week cycle and titrated to tolerance (maximum 800mg) by the treating physician in the first intervention period/initial treatment period.","id":"OG001","title":"Phase II - Analysis Group 2 Pazopanib"}],"paramType":"MEDIAN","populationDescription":"Phase II Analysis Group 2 - Initial Treatment Period","reportingStatus":"POSTED","timeFrame":"Time between randomization and death due to any cause (or last contact for surviving patients and those lost to follow-up), assessed up to 2 years","title":"Overall Survival (OS) (Phase II Analysis Group 2 - Initial Treatment Period)","type":"SECONDARY","unitOfMeasure":"months"}